Medical Devices APAC

APAC Colorectal Cancer Screening Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Colorectal Cancer Screening Market Industry Trends and Forecast to 2034: Segmented by (Test, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.81 Bn Placeholder estimate
Estimate 2025 $1.96 Bn 22.8% of the global market
Projected 2034 $3.92 Bn 99.9% Adds $1.96 Bn over 9 forecast years
CAGR 2025–2034 8.0% Faster than 25% of 186 Medical Devices markets here
Key players 6 +1
  • APAC is 22.82% of the global market.
  • Among regions, the largest is North America at $3.85 Bn.
  • Fastest growing: Africa at 8.3% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.96 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Colorectal Cancer Screening Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.81 Bn — —
2025 (base) $1.96 Bn +$145.1 Mn —
2026 (forecast) $2.12 Bn +$156.8 Mn +8%
2027 (forecast) $2.29 Bn +$169.3 Mn +16.6%
2028 (forecast) $2.47 Bn +$182.8 Mn +26%
2029 (forecast) $2.67 Bn +$197.5 Mn +36%
2030 (forecast) $2.88 Bn +$213.3 Mn +46.9%
2031 (forecast) $3.11 Bn +$230.3 Mn +58.7%
2032 (forecast) $3.36 Bn +$248.8 Mn +71.4%
2033 (forecast) $3.63 Bn +$268.7 Mn +85.1%
2034 (forecast) $3.92 Bn +$290.1 Mn +99.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Colorectal Cancer Screening Market Analysis at a glance
Market size, 2025$1.96 Bn placeholder estimate
Forecast, 2034$3.92 Bn placeholder estimate
Growth (CAGR), 2025–20348.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, setting and end user (see all)
Key playersExact Sciences Corporation, Guardant Health, Inc., Olympus Corporation, Quidel Corporation, Eiken Chemical and 1 more (see all)
Active clinical trials22 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Colorectal Cancer Screening Market Analysis Executive Summary

Colorectal cancer screening finds bowel cancer and pre-cancer early, using stool tests, blood tests and colonoscopy.

Key segments of the colorectal Cancer Screening market include test (Stool DNA Tests, FIT Tests and Blood-Based Tests) and setting (At-Home, Clinics and Hospitals).

Bar chart: Asia Pacific Colorectal Cancer Screening market size, 2024–2034, placeholder estimates. $1.81 Bn in 2024, $1.96 Bn in 2025 and $3.92 Bn in 2034, 8.0% CAGR.
Asia Pacific Colorectal Cancer Screening market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Colorectal Cancer Screening Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the colorectal Cancer Screening market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the colorectal Cancer Screening market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the colorectal Cancer Screening market, especially in low- and middle-income countries.

Competitive Landscape for Colorectal Cancer Screening Market in APAC

The colorectal Cancer Screening market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Colorectal Cancer Screening Market in APAC

Colorectal Cancer Screening in APAC: rules, payment and research

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], Ministry of Health (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Ministry of Health (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28]. ClinicalTrials.gov lists 22 studies on Colorectal Cancer Screening that are recruiting, active or about to start in APAC.⁠[29]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Ministry of Health of Indonesia. Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Ministry of Health of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

[29] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how colorectal Cancer Screening products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Colorectal Cancer Screening right now, from free public sources.

Clinical trials

22 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Jubaan Ltd. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Guardant Health, Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Neptune Medical 2 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Natera 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Singlera Genomics Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Colorectal Cancer Screening in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Colorectal Cancer Screening market in Asia Pacific?
Placeholder estimate: about $1.96 Bn in 2025, rising to about $3.92 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Colorectal Cancer Screening market in Asia Pacific growing?
Placeholder estimate: about 8.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Colorectal Cancer Screening market report cover?
The report splits the market by test (Stool DNA Tests, FIT Tests, Blood-Based Tests, Colonoscopy and more), setting (At-Home, Clinics, Hospitals) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Colorectal Cancer Screening market?
Key players include Exact Sciences Corporation, Guardant Health, Inc., Olympus Corporation, Quidel Corporation, Eiken Chemical and FUJIFILM Holdings Corporation.
What is driving the Colorectal Cancer Screening market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the colorectal Cancer Screening market. Faster approvals and new combinations are improving survival.
How many clinical trials on Colorectal Cancer Screening are running in Asia Pacific?
22 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Colorectal Cancer Screening?
PubMed lists 3,251 papers on Colorectal Cancer Screening added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on oncology and diagnostics and lab testing

See the topic